첫 번째 재발 B-세포 급성 림프구성 백혈병(B-ALL)으로 진단된 환자에서 블리나투모맙 단독 요법과 니볼루맙 병용 블리나투모맙을 비교하는 연구
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
- 절차: Bone Marrow Biopsy
- 생물학적: Nivolumab
- 생물학적: Blinatumomab
- 절차: Bone Marrow Aspiration
- 절차: Lumbar Puncture
- 의약품: Mercaptopurine
- 의약품: Pegaspargase
- 의약품: Calaspargase Pegol
- 의약품: Dexamethasone
- 의약품: Asparaginase Erwinia chrysanthemi
- 의약품: Cytarabine
- 절차: Biospecimen Collection
- 의약품: Hydrocortisone Sodium Succinate
- 의약품: Methotrexate
- 방사능: 3-Dimensional Conformal Radiation Therapy
- 의약품: Vincristine Sulfate
상세 설명
PRIMARY OBJECTIVES:
I. To compare event free survival post reinduction (EFS PR) between blinatumomab vs. blinatumomab/nivolumab in Group 4 patients aged ≥ 1 to <31 years old with first relapse of CD19+ B ALL.
II. To compare EFS PR (EFS post-reinduction) between consolidation with blinatumomab vs. blinatumomab/nivolumab in Group 3 patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
SECONDARY OBJECTIVES:
I. To evaluate the safety and tolerability of blinatumomab/nivolumab in patients aged >= 1 to < 31 years old with first relapse of CD19+ B ALL.
EXPLORATORY OBJECTIVES:
I. In Group 4 patients, compare EFS PR between blinatumomab monotherapy and blinatumomab/nivolumab arms as compared to similar patients treated on the predecessor trial AALL1331.
II. In Group 4 patients, compare toxicity as defined by grade 3 or greater adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab.
III. In Group 4 patients, compare MRD negative second remission (Rem-2) rate after the first cycle of immunotherapy between blinatumomab monotherapy and blinatumomab/nivolumab arms.
IV. In patients with Down syndrome (DS) with first relapse of B-ALL, describe the safety, tolerability and efficacy (as defined by MRD negative second remission, Rem-2) after up to two cycles of blinatumomab/nivolumab.
V. With each Group, perform subset analyses of EFS and overall survival (OS) based on features including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count at first relapse.
OUTLINE:
Patients >= 18 years old with marrow +/- extramedullary (EM) relapse of any duration after initial diagnosis, or patients < 18 years old with marrow +/- EM relapse < 24 months after initial diagnosis are assigned to Group 1. Patients < 18 years old with marrow +/- EM relapse >= 24 months from initial diagnosis, or all isolated extramedullary (IEM) relapses >= 1 to < 31 years old are assigned to Groups 2-3 re-induction. Patients with DS are assigned to Arm G. NOTE: Patients in Group 1 and DS patients with white blood cells (WBC) >= 30,000/uL, CNS 2/3 disease, or testicular disease must first receive 1 of 3 pre-immunotherapy treatments.
Starting with amendment 4C (9/19/2024), patients with DS are assigned to group 3 or 4. Patients < 18 years with bone marrow first relapse ≥ 36 months from initial diagnosis with MRD <0.1% after VXLD reinduction or with isolated CNS/testicular extramedullary relapse occurring ≥ 18 months from initial diagnosis with MRD <0.1% after VXLD reinduction are assigned to group 3. Patients who do not meet criteria for group 3 will be assigned to group 4. Patients with Down syndrome ≥ 1 to < 31 years of age with first bone marrow relapse of B ALL are assigned to arm G.
PRE-IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH WBC >= 30,000/uL (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G) : Patients receive methotrexate (MTX) intrathecally (IT) or cytarabine IT or intrathecal triple therapy (ITT) consisting of MTX, hydrocortisone sodium succinate, and cytarabine IT at the time of diagnostic lumbar puncture (LP) or on day 1 (if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients also receive dexamethasone intravenously (IV) or orally (PO) twice daily (BID) on days 1-5, vincristine sulfate via infusion or IV push over 1 minute on day 1. Patients with DS also receive leucovorin calcium PO or IV every 6 hours (q6h) for 2 doses on day 2 or at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 8 and no later than Day 15.
PRE-IMMUNOTHERAPY TREATMENT FOR CNS 2/3 DISEASE (CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT or cytarabine IT twice weekly (Q2W) for 5-7 doses or Intrathecal Triple Therapy (ITT) IT Q2W for 3-4 doses until patient is CNS 1. Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses at 24 and 30 hours after each IT administration. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 24.
PRE-IMMUNOTHERAPY TREATMENT FOR TESTICULAR DISEASE(CLOSED TO ACCRUAL 9/19/2024 EXCEPT FOR ARM G): Patients receive MTX IT, cytarabine IT, or ITT IT on days 1 and 15 (day 1 may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of protocol therapy). Patients with DS also receive leucovorin calcium PO or IV q6h for 2 doses on days 2 and 16 or at 24 and 30 hours after each IT administration. Males with testicular disease at relapse undergo radiation once daily (QD) for a total of 12 fractions over 12 days. Patients should proceed to the next cycle when CNS 1 and no testicular disease is present, no sooner than Day 15 and no later than Day 22.
GROUP 1 (CLOSED TO ACCRUAL 9/19/2024): Patients are randomized to Arm A or Arm B.
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM B: Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUPS 2-4 VXLD REINDUCTION: Patients receive vincristine sulfate via infusion or IV push over 1 minute on days 1, 8, 15, and 22, dexamethasone PO or IV on days 1-14, doxorubicin hydrochloride IV over 3-15 minutes on day 1, MTX IT on days 1, 8, and 29 (day 1 IT may be omitted if intrathecal therapy is given with relapse diagnostic LP < 7 days prior to the start of this cycle) (days 8 and 29 for CNS 1 patients at relapse only), pegaspargase intramuscularly (IM) or IV over 1-2 hours on days 2 and 16 or calaspargase IV over 1-2 hours on day 2 (for patients ≤ 22 years), cytarabine IT on days 4 and 11 (CNS 2 patients at relapse only), then Q2W until 3 consecutive samples are clear of blasts, and ITT IT on days 8, 15, 22, and 29 (CNS 3 patients at relapse only). Patients with CNS 2 disease at relapse that does not resolve to CNS 1 by day 15 receive maintenance chemoradiation before initiation of maintenance. Treatment continues in the absence of disease progression or unacceptable toxicity.
GROUP 2 (CLOSED TO ACCRUAL 9/19/2024): The following patients are randomized to Arm C or Arm D: 1) >= 1 to < 31 years old, IEM relapse < 18 months from diagnosis, regardless of MRD after Re-Induction. 2) < 18 years old with marrow relapse >= 24 to < 36 months from diagnosis regardless of MRD after Re-Induction, 3) >= 1 to < 31 years old, IEM relapse >= 18 months, and MRD >= 0.1% after Re-Induction, 4) < 18 years old with marrow relapse >= 36 months, and MRD >= 0.1% after Re-Induction.
ARM C: Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and MTX IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal MTX is given < 7 days prior to the start of cycle 1 ). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
ARM D: Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
GROUP 3: Patients are randomized to Arm E or Arm F.
ARM E:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION: Patients receive dexamethasone PO or IV on days 1-5, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 (Omit day 1 for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
ARM F:
IMMUNOTHERAPY CYCLES 1-2: Patients receive dexamethasone PO or IV on day 1 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and on days 1 of cycles 2 and 3, and MTX IT on days 1 and 15 (CNS 1/2 patients at relapse only)(day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle) or , ITT IT on days 1 and 15 (CNS 3 patients at relapse only) (day 1 may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Immunotherapy cycles 1-2 alternate with Consolidation cycles 1-2.
CONSOLIDATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, methotrexate IV, over 24 hours, on days 8 and 22, methotrexate IT on days 8 and 22 (CNS 1/2 at relapse only) or ITT IT on days 8 and 22 (CNS 3 at relapse only).
INTENSIFICATION CYCLES 1-2: Patients receive dexamethasone PO on days 1-5, vincristine sulfate IV push over 1 minute or via infusion on day 1, mercaptopurine PO on days 1-42, methotrexate IV over 24 hours on days 8 and 22, cytarabine IV, over 3 hours on days 43 and 44, asparaginase erwinia chrysanthemi IM on day 44, methotrexate IT on days 1 and 43 (CNS 1/2 at relapse only) or ITT IT on days 1 and 43 (CNS 3 at relapse only).
IMMUNOTHERAPY CYCLE 3: Patients receive blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on day 1 and MTX IT on days 1 and 15 (CNS 1/2 at relapse only) or ITT IT on days 1 and 15 (CNS 3 at relapse only).
MAINTENANCE: Patients receive dexamethasone PO BID on days 1-5, 29-33, and 57-61, vincristine sulfate IV push over 1 minute or via infusion on days 1, 29, and 57, mercaptopurine PO on days 1-84, MTX IT on day 1 (only for patients who did not receive cranial radiation), and MTX PO on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78 (Omit for patients receiving day 1 IT MTX). Treatment repeats every 12 weeks for 2 years from the start of Re-Induction therapy in the absence of disease progression or unacceptable toxicity.
MAINTENANCE CHEMORADIATION: Prior to the first cycle of maintenance therapy, patients with CNS 3 at relapse or CNS 2 at relapse that did not resolve to CNS 1 by day 15 of VXLD Reinduction receive dexamethasone PO BID on days 1-7 and 15-21, vincristine sulfate IV push over 1 minute or via infusion on days 1, 8, and 15, and pegaspargase IM or IV over 1-2 hours or calaspargase IV over 1-2 hours on day 1. Patients with CNS 3 and isolated CNS relapse undergo cranial radiation in the form of 3-dimensional (D)-conformal radiation therapy (CRT) over 5 days per week for a total of 10 treatments.
GROUP 4: Patients are randomized to arm H or arm I.
ARM H: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM I: Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 36 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
ARM G (DS PATIENTS): Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS 1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician.
Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study.
After completion of study treatment, patients are followed up every 3 months for 1 year.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Birmingham, Alabama, 미국, 35233
- 모병
- Children's Hospital of Alabama
-
연락하다:
- Site Public Contact
- 전화번호: 205-638-9285
- 이메일: oncologyresearch@peds.uab.edu
-
수석 연구원:
- Matthew A. Kutny
-
Mobile, Alabama, 미국, 36604
- 모병
- USA Health Strada Patient Care Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-388-8721
-
수석 연구원:
- Hamayun Imran
-
-
Alaska
-
Anchorage, Alaska, 미국, 99508
- 모병
- Providence Alaska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 907-212-6871
- 이메일: AKPAMC.OncologyResearchSupport@providence.org
-
수석 연구원:
- Brenda J. Wittman
-
-
Arizona
-
Kingman, Arizona, 미국, 86401
- 정지된
- Kingman Regional Medical Center
-
Mesa, Arizona, 미국, 85202
- 모병
- Banner Children's at Desert
-
연락하다:
- Site Public Contact
- 전화번호: 480-412-3100
-
수석 연구원:
- Joseph C. Torkildson
-
Phoenix, Arizona, 미국, 85016
- 모병
- Phoenix Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 602-546-0920
-
수석 연구원:
- Dana B. Salzberg
-
Tucson, Arizona, 미국, 85719
- 모병
- Banner University Medical Center - Tucson
-
연락하다:
- Site Public Contact
- 이메일: UACC-IIT@uacc.arizona.edu
-
수석 연구원:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72202-3591
- 모병
- Arkansas Children's Hospital
-
수석 연구원:
- Michael W. Bishop
-
연락하다:
- Site Public Contact
- 전화번호: 501-364-7373
-
-
California
-
Anaheim, California, 미국, 92806
- 정지된
- Kaiser Permanente-Anaheim
-
Arroyo Grande, California, 미국, 93420
- 정지된
- PCR Oncology
-
Bellflower, California, 미국, 90706
- 정지된
- Kaiser Permanente-Bellflower
-
Downey, California, 미국, 90242
- 모병
- Kaiser Permanente Downey Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 626-564-3455
-
수석 연구원:
- Robert M. Cooper
-
Duarte, California, 미국, 91010
- 모집하지 않고 적극적으로
- City of Hope Comprehensive Cancer Center
-
Fontana, California, 미국, 92335
- 모병
- Kaiser Permanente-Fontana
-
연락하다:
- Site Public Contact
- 전화번호: 800-398-3996
- 이메일: clinical.trials@kp.org
-
수석 연구원:
- Robert M. Cooper
-
Loma Linda, California, 미국, 92354
- 모병
- Loma Linda University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 909-558-4050
-
수석 연구원:
- Albert Kheradpour
-
Long Beach, California, 미국, 90806
- 모병
- Miller Children's and Women's Hospital Long Beach
-
연락하다:
- Site Public Contact
- 전화번호: 562-933-5600
-
수석 연구원:
- Jacqueline N. Casillas
-
Los Angeles, California, 미국, 90027
- 모병
- Children's Hospital Los Angeles
-
연락하다:
- Site Public Contact
- 전화번호: 323-361-4110
-
수석 연구원:
- Jamie L. Stokke
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars-Sinai Medical Center
-
수석 연구원:
- Nicole M. Baca
-
연락하다:
- Site Public Contact
- 전화번호: 310-423-2133
- 이메일: Cancer.trial.info@cshs.org
-
Los Angeles, California, 미국, 90095
- 모병
- Mattel Children's Hospital UCLA
-
연락하다:
- Site Public Contact
- 전화번호: 310-825-6708
-
수석 연구원:
- Satiro N. De Oliveira
-
Los Angeles, California, 미국, 90027
- 정지된
- Kaiser Permanente Los Angeles Medical Center
-
Madera, California, 미국, 93636
- 모병
- Valley Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 559-353-3000
- 이메일: Research@valleychildrens.org
-
수석 연구원:
- Ruetima Titapiwatanakun
-
Oakland, California, 미국, 94611
- 모병
- Kaiser Permanente-Oakland
-
연락하다:
- Site Public Contact
- 전화번호: 877-642-4691
- 이메일: Kpoct@kp.org
-
수석 연구원:
- Aarati V. Rao
-
Orange, California, 미국, 92868
- 모병
- Children's Hospital of Orange County
-
연락하다:
- Site Public Contact
- 전화번호: 714-509-8646
- 이메일: oncresearch@choc.org
-
수석 연구원:
- Elyssa M. Rubin
-
Palo Alto, California, 미국, 94304
- 모병
- Lucile Packard Children's Hospital Stanford University
-
연락하다:
- Site Public Contact
- 전화번호: 800-694-0012
- 이메일: ccto-office@stanford.edu
-
수석 연구원:
- Jay Michael S. Balagtas
-
Sacramento, California, 미국, 95817
- 모병
- University of California Davis Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 916-734-3089
-
수석 연구원:
- Marcio H. Malogolowkin
-
Sacramento, California, 미국, 95816
- 모병
- Sutter Medical Center Sacramento
-
연락하다:
- Site Public Contact
- 이메일: clinicalresearch@sutterhealth.org
-
수석 연구원:
- Sandra Baril
-
San Diego, California, 미국, 92120
- 모병
- Kaiser Permanente-San Diego Zion
-
연락하다:
- Site Public Contact
- 전화번호: 800-398-3996
- 이메일: clinical.trials@kp.org
-
수석 연구원:
- Robert M. Cooper
-
San Diego, California, 미국, 92123
- 모병
- Rady Children's Hospital - San Diego
-
연락하다:
- Site Public Contact
- 전화번호: 858-966-5934
-
수석 연구원:
- William D. Roberts
-
San Francisco, California, 미국, 94158
- 모병
- UCSF Medical Center-Mission Bay
-
연락하다:
- Site Public Contact
- 전화번호: 877-827-3222
- 이메일: cancertrials@ucsf.edu
-
수석 연구원:
- Karen R. Rabin
-
Torrance, California, 미국, 90502
- 모집하지 않고 적극적으로
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
수석 연구원:
- Kelly E. Faulk
-
연락하다:
- Site Public Contact
- 전화번호: 303-764-5056
- 이메일: josh.b.gordon@nsmtp.kp.org
-
Denver, Colorado, 미국, 80218
- 모병
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 303-832-2344
- 이메일: PSGResearchSharedMailbox@HCAHealthcare.com
-
수석 연구원:
- Florence Choo
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 860-545-9981
-
수석 연구원:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington, Delaware, 미국, 19803
- 모병
- Alfred I duPont Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
수석 연구원:
- Jeffrey S. Dome
-
연락하다:
- Site Public Contact
- 전화번호: 202-476-2800
- 이메일: OncCRC_OnCall@childrensnational.org
-
Washington D.C., District of Columbia, 미국, 20007
- 모병
- MedStar Georgetown University Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 202-444-2223
-
수석 연구원:
- Caileigh Pudela
-
-
Florida
-
Fort Myers, Florida, 미국, 33908
- 모병
- Golisano Children's Hospital of Southwest Florida
-
연락하다:
- Site Public Contact
- 전화번호: 239-343-5333
- 이메일: molly.arnstrom@leehealth.org
-
수석 연구원:
- Emad K. Salman
-
Gainesville, Florida, 미국, 32610
- 모병
- UF Health Cancer Institute - Gainesville
-
수석 연구원:
- Brian Stover
-
연락하다:
- Site Public Contact
- 전화번호: 352-273-8010
-
Hollywood, Florida, 미국, 33021
- 모병
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 954-265-1847
- 이메일: OHR@mhs.net
-
수석 연구원:
- Iftikhar Hanif
-
Jacksonville, Florida, 미국, 32207
- 모병
- Nemours Children's Clinic-Jacksonville
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
Orlando, Florida, 미국, 32806
- 모병
- Arnold Palmer Hospital for Children
-
수석 연구원:
- Jaime M. Libes-Bander
-
연락하다:
- Site Public Contact
- 전화번호: 321-841-5357
- 이메일: Jennifer.spinelli@orlandohealth.com
-
Orlando, Florida, 미국, 32827
- 모병
- Nemours Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 302-651-5572
- 이메일: Allison.bruce@nemours.org
-
수석 연구원:
- Emi H. Caywood
-
Orlando, Florida, 미국, 32803
- 모병
- AdventHealth Orlando
-
연락하다:
- Site Public Contact
- 전화번호: 407-303-2090
- 이메일: FH.Cancer.Research@flhosp.org
-
수석 연구원:
- Fouad M. Hajjar
-
Pensacola, Florida, 미국, 32504
- 정지된
- Sacred Heart Hospital
-
Pensacola, Florida, 미국, 32504
- 모병
- Nemours Children's Clinic - Pensacola
-
연락하다:
- Site Public Contact
- 이메일: helpdesk@childrensoncologygroup.org
-
수석 연구원:
- Jeffrey H. Schwartz
-
St. Petersburg, Florida, 미국, 33701
- 모병
- Johns Hopkins All Children's Hospital
-
수석 연구원:
- Jennifer L. Mayer
-
연락하다:
- Site Public Contact
- 전화번호: 727-767-4784
- 이메일: Ashley.Repp@jhmi.edu
-
Tampa, Florida, 미국, 33606
- 모병
- Tampa General Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 813-844-7829
- 이메일: syapchanyk@tgh.org
-
수석 연구원:
- Andrew J. Galligan
-
Tampa, Florida, 미국, 33607
- 모병
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
연락하다:
- Site Public Contact
- 전화번호: 813-357-0849
- 이메일: jennifer.manns@baycare.org
-
수석 연구원:
- Don E. Eslin
-
West Palm Beach, Florida, 미국, 33407
- 모병
- Saint Mary's Medical Center
-
수석 연구원:
- Matthew D. Ramirez
-
연락하다:
- Site Public Contact
- 전화번호: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
수석 연구원:
- Waitman K. Aumann
-
연락하다:
- Site Public Contact
- 전화번호: 404-785-0232
- 이메일: Olivia.Floyd@choa.org
-
Savannah, Georgia, 미국, 31404
- 모병
- Memorial Health University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 912-350-7887
- 이메일: Lorraine.OHara@hcahealthcare.com
-
수석 연구원:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96826
- 모병
- Kapiolani Medical Center for Women and Children
-
연락하다:
- Site Public Contact
- 전화번호: 808-983-6090
-
수석 연구원:
- Wade T. Kyono
-
-
Idaho
-
Boise, Idaho, 미국, 83712
- 모병
- Saint Luke's Cancer Institute - Boise
-
수석 연구원:
- Martha M. Pacheco
-
연락하다:
- Site Public Contact
- 전화번호: 208-381-2774
- 이메일: eslinget@slhs.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Lurie Children's Hospital-Chicago
-
연락하다:
- Site Public Contact
- 전화번호: 773-880-4562
-
수석 연구원:
- Jenna Rossoff
-
Chicago, Illinois, 미국, 60637
- 모병
- University of Chicago Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 773-702-8222
- 이메일: cancerclinicaltrials@bsd.uchicago.edu
-
수석 연구원:
- Gabrielle Lapping-Carr
-
Chicago, Illinois, 미국, 60612
- 모병
- University of Illinois
-
연락하다:
- Site Public Contact
- 전화번호: 312-355-3046
-
수석 연구원:
- Dipti S. Dighe
-
Maywood, Illinois, 미국, 60153
- 모병
- Loyola University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 708-226-4357
-
수석 연구원:
- Eugene Suh
-
Peoria, Illinois, 미국, 61637
- 모병
- OSF Children's Hospital of Illinois
-
수석 연구원:
- Prerna Kumar
-
연락하다:
- Site Public Contact
- 전화번호: 309-624-4945
- 이메일: ChildrensHospitalofIllinois@osfhealthcare.org
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Riley Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 800-248-1199
-
수석 연구원:
- Sandeep Batra
-
Indianapolis, Indiana, 미국, 46260
- 모병
- Ascension Saint Vincent Indianapolis Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 317-338-2194
- 이메일: research@stvincent.org
-
수석 연구원:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, 미국, 50309
- 모병
- Blank Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 515-241-8912
- 이메일: samantha.mallory@unitypoint.org
-
수석 연구원:
- Samantha L. Mallory
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa/Holden Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-237-1225
-
수석 연구원:
- Andrew P. Groves
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40536
- 모병
- University of Kentucky/Markey Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 859-257-3379
-
수석 연구원:
- James T. Badgett
-
Louisville, Kentucky, 미국, 40202
- 모병
- Norton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 502-629-5500
- 이메일: CancerResource@nortonhealthcare.org
-
수석 연구원:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70118
- 모병
- Children's Hospital New Orleans
-
수석 연구원:
- Maria C. Velez-Yanguas
-
연락하다:
- Site Public Contact
- 전화번호: 504-894-5377
-
New Orleans, Louisiana, 미국, 70121
- 모집하지 않고 적극적으로
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, 미국, 04401
- 모병
- Eastern Maine Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 207-973-4274
-
수석 연구원:
- Daniel L. Callaway
-
Scarborough, Maine, 미국, 04074
- 모병
- Maine Children's Cancer Program
-
수석 연구원:
- Eric C. Larsen
-
연락하다:
- Site Public Contact
- 전화번호: 207-396-8670
- 이메일: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, 미국, 21287
- 모병
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
수석 연구원:
- Stacy L. Cooper
-
연락하다:
- Site Public Contact
- 전화번호: 410-955-8804
- 이메일: jhcccro@jhmi.edu
-
Baltimore, Maryland, 미국, 21215
- 모병
- Sinai Hospital of Baltimore
-
수석 연구원:
- Jason M. Fixler
-
연락하다:
- Site Public Contact
- 전화번호: 410-601-9083
-
Bethesda, Maryland, 미국, 20889-5600
- 정지된
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02111
- 모집하지 않고 적극적으로
- Tufts Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- C S Mott Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-865-1125
-
수석 연구원:
- Joshua W. Goldman
-
Battle Creek, Michigan, 미국, 49017
- 정지된
- Bronson Battle Creek
-
Dearborn, Michigan, 미국, 48124
- 정지된
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, 미국, 48201
- 정지된
- Children's Hospital of Michigan
-
East Lansing, Michigan, 미국, 48823
- 모집하지 않고 적극적으로
- Michigan State University
-
Grand Rapids, Michigan, 미국, 49503
- 정지된
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, 미국, 49503
- 모병
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
Grand Rapids, Michigan, 미국, 49503
- 정지된
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, 미국, 49007
- 모병
- Bronson Methodist Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 616-391-1230
- 이메일: crcwm-regulatory@crcwm.org
-
수석 연구원:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, 미국, 49007
- 정지된
- West Michigan Cancer Center
-
Kalamazoo, Michigan, 미국, 49048
- 정지된
- Beacon Kalamazoo
-
Muskegon, Michigan, 미국, 49444
- 정지된
- Trinity Health Muskegon Hospital
-
Niles, Michigan, 미국, 49120
- 정지된
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, 미국, 49444
- 정지된
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, 미국, 49677
- 정지된
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, 미국, 48073
- 모병
- Corewell Health Children's
-
연락하다:
- Site Public Contact
- 전화번호: 248-551-7695
-
수석 연구원:
- Marie V. Nelson
-
Royal Oak, Michigan, 미국, 48073
- 정지된
- Corewell Health William Beaumont University Hospital
-
Saint Joseph, Michigan, 미국, 49085
- 정지된
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, 미국, 49085
- 정지된
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, 미국, 49684
- 정지된
- Munson Medical Center
-
Troy, Michigan, 미국, 48085
- 정지된
- Corewell Health Beaumont Troy Hospital
-
Wyoming, Michigan, 미국, 49519
- 정지된
- University of Michigan Health - West
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55404
- 모병
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
수석 연구원:
- Michael K. Richards
-
연락하다:
- Site Public Contact
- 전화번호: 612-813-5913
- 이메일: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota/Masonic Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 612-624-2620
-
수석 연구원:
- Peter M. Gordon
-
-
Mississippi
-
Jackson, Mississippi, 미국, 39216
- 모병
- University of Mississippi Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 601-815-6700
-
수석 연구원:
- Amanda Strobel
-
-
Missouri
-
Kansas City, Missouri, 미국, 64108
- 모병
- Children's Mercy Hospitals and Clinics
-
수석 연구원:
- Keith J. August
-
연락하다:
- Site Public Contact
- 전화번호: 816-302-6808
- 이메일: COGResearchGroup@cmh.edu
-
St Louis, Missouri, 미국, 63110
- 모병
- Washington University School of Medicine
-
연락하다:
- Site Public Contact
- 전화번호: 800-600-3606
- 이메일: info@siteman.wustl.edu
-
수석 연구원:
- Kristin Zorn
-
St Louis, Missouri, 미국, 63141
- 모병
- Mercy Hospital Saint Louis
-
연락하다:
- Site Public Contact
- 전화번호: 314-251-7066
-
수석 연구원:
- Robin D. Hanson
-
St Louis, Missouri, 미국, 63104
- 모병
- Cardinal Glennon Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 314-268-4000
-
수석 연구원:
- William S. Ferguson
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68114
- 모병
- Children's Hospital and Medical Center of Omaha
-
연락하다:
- Site Public Contact
- 전화번호: 402-955-3949
-
수석 연구원:
- Jill C. Beck
-
Omaha, Nebraska, 미국, 68198
- 모병
- University of Nebraska Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 402-559-6941
- 이메일: unmcrsa@unmc.edu
-
수석 연구원:
- Jill C. Beck
-
-
Nevada
-
Carson City, Nevada, 미국, 89703
- 정지된
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, 미국, 89052
- 정지된
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, 미국, 89052
- 정지된
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, 미국, 89052
- 정지된
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, 미국, 89074
- 정지된
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Las Vegas, Nevada, 미국, 89135
- 모병
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
연락하다:
- Site Public Contact
- 전화번호: 702-384-0013
- 이메일: research@sncrf.org
-
수석 연구원:
- Joseph L. Lasky
-
Las Vegas, Nevada, 미국, 89144
- 모병
- Summerlin Hospital Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 702-384-0013
- 이메일: research@sncrf.org
-
수석 연구원:
- Joseph L. Lasky
-
Las Vegas, Nevada, 미국, 89103
- 정지된
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, 미국, 89109
- 정지된
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, 미국, 89128
- 정지된
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, 미국, 89128
- 정지된
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, 미국, 89128
- 정지된
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, 미국, 89144
- 정지된
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, 미국, 89144
- 정지된
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, 미국, 89148-2405
- 정지된
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, 미국, 89148
- 정지된
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, 미국, 89169
- 정지된
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, 미국, 89102
- 정지된
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, 미국, 89183
- 정지된
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, 미국, 89048
- 정지된
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, 미국, 89502
- 모병
- Renown Regional Medical Center
-
수석 연구원:
- Seema L. Rao
-
연락하다:
- Site Public Contact
- 전화번호: 775-982-5050
- 이메일: Renown-CRD@renown.org
-
Reno, Nevada, 미국, 89503
- 정지된
- Saint Mary's Regional Medical Center
-
Reno, Nevada, 미국, 89511
- 정지된
- Cancer Care Specialists - Reno
-
-
New Hampshire
-
Lebanon, New Hampshire, 미국, 03756
- 모병
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
수석 연구원:
- Angela Ricci
-
연락하다:
- Site Public Contact
- 전화번호: 800-639-6918
- 이메일: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- 모병
- Hackensack University Medical Center
-
수석 연구원:
- Jing Chen
-
연락하다:
- Site Public Contact
- 전화번호: 551-996-2897
-
Morristown, New Jersey, 미국, 07960
- 모병
- Morristown Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-971-5900
-
수석 연구원:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-7356
-
수석 연구원:
- Richard A. Drachtman
-
New Brunswick, New Jersey, 미국, 08901
- 모병
- Saint Peter's University Hospital
-
수석 연구원:
- Nibal A. Zaghloul
-
연락하다:
- Site Public Contact
- 전화번호: 732-745-8600
- 이메일: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, 미국, 08903
- 모병
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 732-235-8675
-
수석 연구원:
- Richard A. Drachtman
-
Newark, New Jersey, 미국, 07112
- 모병
- Newark Beth Israel Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-926-7230
- 이메일: Christine.Kosmides@rwjbh.org
-
수석 연구원:
- Teena Bhatla
-
Paterson, New Jersey, 미국, 07503
- 모병
- Saint Joseph's Regional Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 973-754-2207
- 이메일: HallL@sjhmc.org
-
수석 연구원:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87106
- 모병
- Presbyterian Hospital
-
수석 연구원:
- Beeling Armijo
-
연락하다:
- Site Public Contact
- 전화번호: 505-559-6113
- 이메일: wburman@phs.org
-
-
New York
-
Albany, New York, 미국, 12208
- 모병
- Albany Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 518-262-5513
-
수석 연구원:
- Lauren R. Weintraub
-
Brooklyn, New York, 미국, 11219
- 모병
- Maimonides Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 718-765-2500
-
수석 연구원:
- Mahmut Y. Celiker
-
Mineola, New York, 미국, 11501
- 모병
- NYU Langone Hospital - Long Island
-
연락하다:
- Site Public Contact
- 전화번호: 212-263-4432
- 이메일: cancertrials@nyulangone.org
-
수석 연구원:
- Chana L. Glasser
-
New Hyde Park, New York, 미국, 11040
- 모병
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
연락하다:
- Site Public Contact
- 전화번호: 718-470-3460
-
수석 연구원:
- Julie I. Krystal
-
New York, New York, 미국, 10032
- 모병
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
수석 연구원:
- Nobuko Hijiya
-
연락하다:
- Site Public Contact
- 전화번호: 212-342-5162
- 이메일: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, 미국, 10065
- 모병
- Memorial Sloan Kettering Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 212-639-7592
-
수석 연구원:
- Kavitha Ramaswamy
-
New York, New York, 미국, 10016
- 모병
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
수석 연구원:
- Elizabeth A. Raetz
-
연락하다:
- Site Public Contact
- 이메일: CancerTrials@nyulangone.org
-
New York, New York, 미국, 10065
- 모병
- NYP/Weill Cornell Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 212-746-1848
-
수석 연구원:
- Jaclyn Rosenzweig
-
Rochester, New York, 미국, 14642
- 모집하지 않고 적극적으로
- University of Rochester
-
Stony Brook, New York, 미국, 11794
- 모병
- Stony Brook University Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-862-2215
-
수석 연구원:
- Laura E. Hogan
-
Syracuse, New York, 미국, 13210
- 모병
- State University of New York Upstate Medical University
-
연락하다:
- Site Public Contact
- 전화번호: 315-464-5476
-
수석 연구원:
- Melanie A. Comito
-
The Bronx, New York, 미국, 10467
- 모병
- Montefiore Medical Center - Moses Campus
-
연락하다:
- Site Public Contact
- 전화번호: 718-379-6866
- 이메일: eskwak@montefiore.org
-
수석 연구원:
- Alice Lee
-
-
North Carolina
-
Asheville, North Carolina, 미국, 28801
- 모병
- Mission Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 828-213-7055
- 이메일: NCDV.ResearchRegulatory@HCAHealthcare.com
-
수석 연구원:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, 미국, 27599
- 모병
- UNC Lineberger Comprehensive Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 877-668-0683
- 이메일: cancerclinicaltrials@med.unc.edu
-
수석 연구원:
- Thomas B. Alexander
-
Charlotte, North Carolina, 미국, 28203
- 모병
- Carolinas Medical Center/Levine Cancer Institute
-
연락하다:
- Site Public Contact
- 전화번호: 800-804-9376
-
수석 연구원:
- Joel A. Kaplan
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke University Medical Center
-
수석 연구원:
- Jessica M. Sun
-
연락하다:
- Site Public Contact
- 전화번호: 888-275-3853
-
Greenville, North Carolina, 미국, 27834
- 모병
- East Carolina University
-
연락하다:
- Site Public Contact
- 전화번호: 252-744-1015
- 이메일: eubankss@ecu.edu
-
수석 연구원:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Wake Forest University Health Sciences
-
연락하다:
- Site Public Contact
- 전화번호: 336-713-6771
-
수석 연구원:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58122
- 모병
- Sanford Broadway Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 701-323-5760
- 이메일: OncologyClinicalTrialsFargo@sanfordhealth.org
-
수석 연구원:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, 미국, 44308
- 모병
- Children's Hospital Medical Center of Akron
-
연락하다:
- Site Public Contact
- 전화번호: 330-543-3193
-
수석 연구원:
- Lauren R. Draper
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 513-636-2799
- 이메일: cancer@cchmc.org
-
수석 연구원:
- Erin H. Breese
-
Cleveland, Ohio, 미국, 44106
- 모병
- Rainbow Babies and Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 216-844-5437
-
수석 연구원:
- Duncan S. Stearns
-
Cleveland, Ohio, 미국, 44195
- 정지된
- Cleveland Clinic Foundation
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 614-722-6039
- 이메일: Melinda.Triplet@nationwidechildrens.org
-
수석 연구원:
- Mark A. Ranalli
-
Dayton, Ohio, 미국, 45404
- 모병
- Dayton Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-4055
-
수석 연구원:
- Jordan M. Wright
-
Sylvania, Ohio, 미국, 43560
- 정지된
- ProMedica Flower Hospital
-
Toledo, Ohio, 미국, 43606
- 모병
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 419-824-1842
- 이메일: PCIOncResearch@promedica.org
-
수석 연구원:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- University of Oklahoma Health Sciences Center
-
연락하다:
- Site Public Contact
- 전화번호: 405-271-8777
- 이메일: ou-clinical-trials@ouhsc.edu
-
수석 연구원:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, 미국, 74136
- 모병
- Saint Francis Children's Hospital
-
수석 연구원:
- Jill A. Salo
-
연락하다:
- Site Public Contact
- 전화번호: 918-502-6720
-
-
Oregon
-
Portland, Oregon, 미국, 97227
- 모병
- Legacy Emanuel Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 503-413-2560
-
수석 연구원:
- Jason M. Glover
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health and Science University
-
연락하다:
- Site Public Contact
- 전화번호: 503-494-1080
- 이메일: trials@ohsu.edu
-
수석 연구원:
- Bill H. Chang
-
-
Pennsylvania
-
Allentown, Pennsylvania, 미국, 18103
- 모병
- Lehigh Valley Hospital-Cedar Crest
-
연락하다:
- Site Public Contact
- 전화번호: 610-402-9543
- 이메일: Morgan_M.Horton@lvhn.org
-
수석 연구원:
- Jacob A. Troutman
-
Danville, Pennsylvania, 미국, 17822
- 모병
- Geisinger Medical Center
-
수석 연구원:
- Jagadeesh Ramdas
-
연락하다:
- Site Public Contact
- 전화번호: 570-271-5251
- 이메일: cancerresearch@geisinger.edu
-
Hershey, Pennsylvania, 미국, 17033
- 모병
- Penn State Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 717-531-6012
-
수석 연구원:
- Lisa M. McGregor
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
수석 연구원:
- Shannon L. Maude
-
연락하다:
- Site Public Contact
- 전화번호: 267-425-5544
- 이메일: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, 미국, 19134
- 모병
- Saint Christopher's Hospital for Children
-
연락하다:
- Site Public Contact
- 전화번호: 215-427-8991
-
수석 연구원:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, 미국, 15224
- 모병
- Children's Hospital of Pittsburgh of UPMC
-
연락하다:
- Site Public Contact
- 전화번호: 412-692-8570
- 이메일: jean.tersak@chp.edu
-
수석 연구원:
- Jenny Ruiz
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- 모병
- Rhode Island Hospital
-
수석 연구원:
- Bradley DeNardo
-
연락하다:
- Site Public Contact
- 전화번호: 401-444-1488
-
-
South Carolina
-
Columbia, South Carolina, 미국, 29203
- 모병
- Prisma Health Richland Hospital
-
수석 연구원:
- Stuart L. Cramer
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, 미국, 29605
- 모병
- BI-LO Charities Children's Cancer Center
-
수석 연구원:
- Aniket Saha
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, 미국, 29615
- 모병
- Prisma Health Cancer Institute - Eastside
-
수석 연구원:
- Aniket Saha
-
연락하다:
- Site Public Contact
- 전화번호: 864-522-4317
- 이메일: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57117-5134
- 모병
- Sanford USD Medical Center - Sioux Falls
-
연락하다:
- Site Public Contact
- 전화번호: 605-312-3320
- 이메일: OncologyClinicalTrialsSF@SanfordHealth.org
-
수석 연구원:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, 미국, 37916
- 모병
- East Tennessee Childrens Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 865-541-8266
-
수석 연구원:
- Susan E. Spiller
-
Nashville, Tennessee, 미국, 37232
- 모병
- Vanderbilt University/Ingram Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 800-811-8480
-
수석 연구원:
- Brianna N. Smith
-
Nashville, Tennessee, 미국, 37203
- 모병
- The Children's Hospital at TriStar Centennial
-
연락하다:
- Site Public Contact
- 전화번호: 615-342-1919
-
수석 연구원:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, 미국, 78723
- 모병
- Dell Children's Medical Center of Central Texas
-
연락하다:
- Site Public Contact
- 전화번호: 512-628-1902
- 이메일: TXAUS-DL-SFCHemonc.research@ascension.org
-
수석 연구원:
- Shannon M. Cohn
-
Corpus Christi, Texas, 미국, 78411
- 모병
- Driscoll Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 361-694-5311
- 이메일: Crystal.DeLosSantos@dchstx.org
-
수석 연구원:
- Nkechi I. Mba
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern/Simmons Cancer Center-Dallas
-
연락하다:
- Site Public Contact
- 전화번호: 214-648-7097
- 이메일: canceranswerline@UTSouthwestern.edu
-
수석 연구원:
- Tamra L. Slone
-
Dallas, Texas, 미국, 75230
- 모병
- Medical City Dallas Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 972-566-5588
-
수석 연구원:
- Maurizio L. Ghisoli
-
El Paso, Texas, 미국, 79905
- 모병
- El Paso Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 915-298-5444
- 이메일: ranjan.bista@ttuhsc.edu
-
수석 연구원:
- Benjamin Carcamo
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Children's Medical Center
-
연락하다:
- Site Public Contact
- 전화번호: 682-885-2103
- 이메일: CookChildrensResearch@cookchildrens.org
-
수석 연구원:
- Kenneth M. Heym
-
Houston, Texas, 미국, 77030
- 모병
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
수석 연구원:
- Anil George
-
연락하다:
- Site Public Contact
- 전화번호: 713-798-1354
- 이메일: burton@bcm.edu
-
Houston, Texas, 미국, 77030
- 모병
- UT MD Anderson Cancer Center
-
연락하다:
- Site Public Contact
- 전화번호: 866-632-6789
- 이메일: askmdanderson@mdanderson.org
-
수석 연구원:
- Najat C. Daw
-
Lubbock, Texas, 미국, 79410
- 모병
- Covenant Children's Hospital
-
수석 연구원:
- Kishor M. Bhende
-
연락하다:
- Site Public Contact
- 전화번호: 806-725-8657
- 이메일: mbisbee@providence.org
-
Lubbock, Texas, 미국, 79415
- 모병
- UMC Cancer Center / UMC Health System
-
연락하다:
- Site Public Contact
- 전화번호: 806-775-8590
-
수석 연구원:
- Erin K. Barr
-
San Antonio, Texas, 미국, 78207
- 모병
- Children's Hospital of San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-704-2894
- 이메일: bridget.medina@christushealth.org
-
수석 연구원:
- Julie Voeller
-
San Antonio, Texas, 미국, 78229
- 모병
- University of Texas Health Science Center at San Antonio
-
연락하다:
- Site Public Contact
- 전화번호: 210-450-3800
- 이메일: phoresearchoffice@uthscsa.edu
-
수석 연구원:
- Anne-Marie R. Langevin
-
San Antonio, Texas, 미국, 78229
- 모병
- Methodist Children's Hospital of South Texas
-
연락하다:
- Site Public Contact
- 전화번호: 210-575-6240
- 이메일: Vinod.GidvaniDiaz@hcahealthcare.com
-
수석 연구원:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, 미국, 84113
- 모병
- Primary Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 801-585-5270
-
수석 연구원:
- Luke D. Maese
-
-
Vermont
-
Burlington, Vermont, 미국, 05405
- 모병
- University of Vermont and State Agricultural College
-
연락하다:
- Site Public Contact
- 전화번호: 802-656-8990
- 이메일: rpo@uvm.edu
-
수석 연구원:
- Jessica L. Heath
-
-
Virginia
-
Falls Church, Virginia, 미국, 22042
- 모병
- Inova Fairfax Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 703-208-6650
- 이메일: Stephanie.VanBebber@inova.org
-
수석 연구원:
- Robin Y. Dulman
-
Norfolk, Virginia, 미국, 23507
- 모병
- Children's Hospital of The King's Daughters
-
연락하다:
- Site Public Contact
- 전화번호: 757-668-7243
- 이메일: CCBDCresearch@chkd.org
-
수석 연구원:
- Melissa S. Mark
-
Richmond, Virginia, 미국, 23298
- 모병
- VCU Massey Comprehensive Cancer Center
-
수석 연구원:
- Jordyn R. Griffin
-
연락하다:
- Site Public Contact
- 전화번호: 804-628-6430
- 이메일: CTOclinops@vcu.edu
-
-
Washington
-
Bellevue, Washington, 미국, 98004
- 정지된
- Overlake Medical Center
-
Renton, Washington, 미국, 98055
- 정지된
- Valley Medical Center
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 866-987-2000
-
수석 연구원:
- Sarah E. Leary
-
Spokane, Washington, 미국, 99204
- 모병
- Providence Sacred Heart Medical Center and Children's Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-228-6618
- 이메일: HopeBeginsHere@providence.org
-
수석 연구원:
- Judy L. Felgenhauer
-
Tacoma, Washington, 미국, 98405
- 모병
- Mary Bridge Children's Hospital and Health Center
-
연락하다:
- Site Public Contact
- 전화번호: 253-403-1461
- 이메일: research@multicare.org
-
수석 연구원:
- Robert G. Irwin
-
Tacoma, Washington, 미국, 98431
- 모병
- Madigan Army Medical Center
-
수석 연구원:
- Melissa A. Forouhar
-
연락하다:
- Site Public Contact
- 전화번호: 253-968-6144
- 이메일: melissa.a.forouhar.mil@health.mil
-
Yakima, Washington, 미국, 98902
- 정지된
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
-
West Virginia
-
Bridgeport, West Virginia, 미국, 26330
- 정지된
- United Hospital Center
-
Charleston, West Virginia, 미국, 25304
- 모병
- Vandalia Health/CAMC Institute for Academic Medicine
-
수석 연구원:
- Mohamad H. Badawi
-
연락하다:
- Site Public Contact
- 전화번호: 304-388-9944
- 이메일: CAMCClinicalTrials@vandaliahealth.org
-
Martinsburg, West Virginia, 미국, 25401
- 정지된
- WVUH-Berkely Medical Center
-
Morgantown, West Virginia, 미국, 26506
- 모병
- West Virginia University Healthcare
-
연락하다:
- Site Public Contact
- 전화번호: 304-293-7374
- 이메일: cancertrialsinfo@hsc.wvu.edu
-
수석 연구원:
- Ashley E. Meyer
-
Parkersburg, West Virginia, 미국, 26101
- 정지된
- Camden Clark Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, 미국, 54301
- 모병
- Saint Vincent Hospital Cancer Center Green Bay
-
수석 연구원:
- Catherine A. Long
-
연락하다:
- Site Public Contact
- 전화번호: 920-433-8889
- 이메일: WI_research_admin@hshs.org
-
Madison, Wisconsin, 미국, 53792
- 모병
- University of Wisconsin Carbone Cancer Center - University Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 800-622-8922
- 이메일: clinicaltrials@cancer.wisc.edu
-
수석 연구원:
- Cathy A. Lee-Miller
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Hospital of Wisconsin
-
연락하다:
- Site Public Contact
- 전화번호: 414-955-4727
- 이메일: MACCCTO@mcw.edu
-
수석 연구원:
- Michael J. Burke
-
-
-
-
-
Québec, 캐나다, G1V 4G2
- 모병
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
수석 연구원:
- Bruno Michon
-
연락하다:
- Site Public Contact
- 전화번호: 418-525-4444
- 이메일: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, 캐나다, T3B 6A8
- 정지된
- Alberta Children's Hospital
-
Edmonton, Alberta, 캐나다, T6G 2B7
- 모병
- University of Alberta Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 780-407-8798
- 이메일: pedsoncologyresearch@ahs.ca
-
수석 연구원:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6H 3V4
- 정지된
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3E 0V9
- 모병
- CancerCare Manitoba
-
연락하다:
- Site Public Contact
- 전화번호: 866-561-1026
- 이메일: ctu_web@cancercare.mb.ca
-
수석 연구원:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1B 3V6
- 모병
- Janeway Child Health Centre
-
수석 연구원:
- Lisa A. Goodyear
-
연락하다:
- Site Public Contact
- 전화번호: 709-777-8727
- 이메일: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3K 6R8
- 모병
- IWK Health Centre
-
연락하다:
- Site Public Contact
- 전화번호: 902-470-8520
- 이메일: Research@iwk.nshealth.ca
-
수석 연구원:
- Chelsea Ash
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3H 1P3
- 모병
- The Montreal Children's Hospital of the MUHC
-
연락하다:
- Site Public Contact
- 전화번호: 514-412-4445
- 이메일: info@thechildren.com
-
수석 연구원:
- Stephanie Mourad
-
Montreal, Quebec, 캐나다, H3T 1C5
- 모병
- Centre Hospitalier Universitaire Sainte-Justine
-
수석 연구원:
- Monia Marzouki
-
연락하다:
- Site Public Contact
- 전화번호: 514-345-4931
- 이메일: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, 캐나다, J1H 5N4
- 모병
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
연락하다:
- Site Public Contact
- 전화번호: 819-820-6480
- 이메일: crcinformation.chus@ssss.gouv.qc.ca
-
수석 연구원:
- Stephanie Vairy
-
-
-
-
-
San Juan, 푸에르토 리코, 00926
- 모병
- University Pediatric Hospital
-
연락하다:
- Site Public Contact
- 전화번호: 787-474-0333
-
수석 연구원:
- Maria E. Echevarria
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre, New South Wales, 호주, 2310
- 정지된
- John Hunter Children's Hospital
-
Randwick, New South Wales, 호주, 2031
- 정지된
- Sydney Children's Hospital
-
Westmead, New South Wales, 호주, 2145
- 정지된
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, 호주, 4101
- 정지된
- Queensland Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, 호주, 6009
- 정지된
- Perth Children's Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Patients must be >= 1 and < 31 years at time of enrollment
-
Patients must have first relapse of CD19+ B-ALL (relapse blasts must express CD19) in one of the following categories:
- Isolated bone marrow relapse
- Isolated central nervous system (CNS) (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
- Combined bone marrow with extramedullary relapse in the CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testes
-
Patients with Down syndrome (DS) are eligible in the following categories:
- Isolated bone marrow relapse
- Combined bone marrow with CNS (excluding known optic nerve/retinal and CNS chloromas) and/or testicular relapse
-
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
- Of note, for patients with developmental delay (e.g., Down syndrome) regardless of age, Lansky scale may be substituted for Karnofsky scale. However, the requirement for ECOG 0-2 remains, regardless of known history of developmental delay
-
Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
-
Patients with prior blinatumomab or CD19+ chimeric antigen receptor therapy in the upfront setting will be eligible, provided relapsed lymphoblasts retain CD19 expression
-
Patients must not have had a prior hematopoietic stem cell transplant
-
A single intrathecal chemotherapy at the time of relapse will be allowed. If < 7 days have elapsed between this intrathecal therapy (IT) and the start of protocol therapy, then the day 1 intrathecal chemotherapy (i.e. methotrexate, cytarabine, or triple intrathecal) may be omitted
-
In the 28 days prior to enrollment, up to five days of post-relapse, pre-enrollment therapy (steroids and/or hydroxyurea only) is permissible
- Patients with Down syndrome who received pre-enrollment therapy and have a white blood count (WBC) >= 30,000/ul at the time of enrollment still must receive protocol specified cytoreductive therapy with vincristine and dexamethasone, and no "washout" is required
- Patients with Down syndrome who received pre-enrollment therapy and have a WBC < 30,000/ul at the time of enrollment must be given a 24 hour "washout" before starting immunotherapy
-
Note: There is no waiting period or "washout" for patients who relapse while receiving upfront therapy
-
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 OR a serum creatinine based on age/sex as follows (within 7 calendar days prior to enrollment):
-
Age: Maximum serum creatinine (mg/dL)
-
1 to < 2 years: 0.6 (male), 0.6 (female)
-
2 to < 6 years: 0.8 (male), 0.8 (female)
-
6 to < 10 years: 1 (male), 1 (female)
-
10 to < 13 years: 1.2 (male), 1.2 (female)
-
13 to < 16 years: 1.5 (male), 1.4 (female)
-
>= 16 years: 1.7 (male), 1.4 (female)
- The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease Control (CDC)
-
-
-
Shortening fraction of >= 27% by echocardiogram, or ejection fraction of >= 50% by echocardiogram, cardiac magnetic resonance imaging (MRI) or radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
-
Patients with B-lymphoblastic lymphoma (B-LLy)
-
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia
-
Patients with Philadelphia chromosome positive (Ph+) B-ALL or ABL class Ph-like B-ALL (i.e. rearrangements involving ABL1, ABL2, CSF1R or PDGFRB and predicted to be sensitive to imatinib or dasatinib)
-
Patients with mixed phenotype acute leukemia (MPAL)
-
Patients with known Charcot-Marie-Tooth disease
-
Patients with known MYC translocation associated with mature (Burkitt) B-cell ALL, regardless of blast immunophenotype
-
Patients with active, uncontrolled infection defined as:
- Positive bacterial blood culture within 48 hours of study enrollment
- Receiving IV or PO antibiotics for an infection with continued signs or symptoms. Note: Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection if cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with clostridium (C.) difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
- Fever above 38.2 degrees Celsius (C) within 48 hours of study enrollment with clinical signs of infection. Fever without clinical signs of infection that is attributed to tumor burden is allowed if blood cultures are negative for > 48 hours
- A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection
- Active viral or protozoal infection requiring IV treatment
-
Patients known to have one of the following concomitant genetic syndromes: Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome are not eligible.
-
Patients with uncontrolled HIV, hepatitis B, or hepatitis C infection. Of note, patients with known human immunodeficiency virus (HIV) infection on effective anti-retroviral therapy with undetectable viral load for at least the last 6 months prior to enrollment are eligible. Similarly, hepatitis B and hepatitis C positive patients who have been treated and have no viral detectable burden are also eligible
-
Patients with significant central nervous system pathology that would preclude treatment with blinatumomab, including history of severe neurologic disorder or autoimmune disease with CNS involvement
- Note: Patients with a history of seizures that are well controlled on stable doses of anti-epileptic drugs are eligible Patients with a history of cerebrovascular ischemia/hemorrhage with residual deficits are not eligible. Patients with a history of cerebrovascular ischemia/hemorrhage remain eligible provided all neurologic deficits have resolved
-
Patients with an active known/suspected autoimmune disease are not eligible. However, patients with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
-
Patients with DS patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are not eligible
- Note: Group 3 and 4 patients with known non-hematopoietic, non-CNS/testicular extramedullary disease (i.e., chloromatous disease) are eligible if this is NOT the only site of relapsed disease
-
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained within 7 days prior to enrollment. Patients who are sexually active and of reproductive potential are not eligible unless they agree to use an effective contraceptive method for the duration of this study. Men with female partners of childbearing potential should use effective contraception during the duration of their treatment. The effect of blinatumomab on fertility has not been evaluated. Blinatumomab is not recommended for pregnant women or women of childbearing potential (WOCBP) not using contraception. Females of reproductive potential must use effective contraception during treatment and for at least 48 hours after the last dose of blinatumomab. Studies in animal models have shown that nivolumab can adversely impair pregnancy. Thus, nivolumab is expected to cause fetal harm during pregnancy. WOCBP receiving nivolumab must continue contraception for a period of at least 5 months after the last dose of nivolumab. It is unknown whether nivolumab is present in breast milk, thus breastfeeding should be discontinued while a patient is receiving nivolumab
-
Lactating females are not eligible unless they agree to not breastfeed their infants. It is unknown whether blinatumomab or its metabolites are excreted in human breast milk. Women are not permitted to breastfeed while receiving blinatumomab and for the last 48 hours after the last blinatumomab dose. Due to the potential for serious adverse reactions in the breastfed infant, women are not permitted to breastfeed during treatment and for 5 months after the last nivolumab dose
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients
Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 of cycle 1 and day 3 of cycle 2, and MTX IT (for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with MRD <0.01% at the end of Cycle 1 may stop study treatment at the discretion of the treating physician. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 1, Arm A (dexamethasone, blinatumomab, MTX)
ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 1, Arm B (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 2, Arm C (dexamethasone, blinatumomab, MTX)
Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)
Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. (CLOSED TO ACCRUAL 9/19/2024) |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 3, Arm E (dexamethasone, blinatumomab, MTX)
See Outline section |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO
다른 이름들:
Given IM or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or IV
다른 이름들:
Given IM
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
Undergo 3D-CRT
다른 이름들:
Given IV push or via infusion
다른 이름들:
|
|
실험적: Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)
See Outline section |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO
다른 이름들:
Given IM or IV
다른 이름들:
Given IV
다른 이름들:
Given PO or IV
다른 이름들:
Given IM
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
Undergo 3D-CRT
다른 이름들:
Given IV push or via infusion
다른 이름들:
|
|
실험적: Group 4 Arm I (Dexamethasone, blinatumomab, nivolumab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV, over 30 minutes on day 11 of cycle 1 and day 3 of cycle 2 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given IV
다른 이름들:
Given PO or IV
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
|
실험적: Group 4, Arm H (dexamethasone blinatumomab)
Patients receive dexamethasone PO or IV on day 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28 and MTX IT on days 1 of cycle 1 only and days 15 and 36 ( for patients with CNS1/2 at relapse only) or ITT on day 1 of cycle 1 only and days 15 and 36 (for patients with CNS 3 at relapse only) (day 1 IT therapy may be omitted from cycle 1 if intrathecal therapy is given with < 7 days prior to the start of this cycle). Cycles repeat every 37 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo lumbar puncture, bone marrow biopsy and aspiration, and collection of blood, urine and cerebrospinal fluid throughout the study. |
Undergo bone marrow biopsy
다른 이름들:
Given IV
다른 이름들:
Undergo bone marrow aspiration Undergo lumbar puncture
다른 이름들:
Given PO or IV
다른 이름들:
Given IT
다른 이름들:
Undergo blood, urine and cerebrospinal fluid collection
다른 이름들:
Given IT
다른 이름들:
Given IT, PO, and IV
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Minimal residual disease (MRD) negative second remission (Rem-2) rate with blinatumomab vs with blinatumomab + nivolumab (Group 1)
기간: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 be defined as Rem-2 (i.e., achievement of MRD < 1% blasts by flow cytometry and resolution of extramedullary disease (for CNS disease, requires CNS 1) ) and bone marrow with MRD < 0.01% by flow cytometry. MRD negative Rem-2 rate between Arm A vs Arm B will be compared using a one-sided Z test of proportions with Type I error of 0.10. Interim analysis will be conducted to monitor for futility. The futility boundaries are based on testing the alternative hypothesis at the 0.067 level. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Event-free survival post-reinduction (EFS PR) (Group 3)
기간: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm E versus Arm F will be based on a one-sided two-sample logrank test with Type I error of 0.15, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
|
EFS PR (Group 4)
기간: From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
Comparison of EFS post reinduction between Arm H versus Arm I will be based on a one-sided two-sample logrank test with Type I error of 0.10, to be conducted 3 years after completion of enrollment of Group 3. Interim analysis will be conducted to monitor for futility. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. This alpha level corresponds to that which would cause futility stopping if the one-sided two-sample logrank test shows evidence of a hazard ratio > 1.0 when half of the expected events are observed. |
From date of randomization to date of treatment failure, relapse, second malignancy (SMN) or death due to any cause, assessed up to 10 years after completion of enrollment.
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Dose-limiting toxicity
기간: Up to 1 cycle of therapy (each cycle = 36 days)
|
Will be assessed using the Common Terminology Criteria for Adverse Events version 5.0. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
기간: From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
Comparison of EFS post-reinduction between Arm C versus Arm D will be based on a one-sided two-sample logrank test with type I error of 0.15, to be conducted 2 years after completion of enrollment of Group 2. The futility monitoring will be based on testing the alternative hypothesis at the 0.092 level. |
From date of randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years after completion of enrollment
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Event-free survival (Group 1)
기간: From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
EFS will be compared between Arm A and Arm B, and to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. |
From date of Group 1 randomization to date of treatment failure, relapse, disease progression, SMN or death due to any cause, assessed up to 5 years
|
|
Event free survival (Group 4)
기간: From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
EFS of Arm H and Arm I will be compared to similar patients treated on AALL1331. These analyses will be performed using logrank tests, semi-parametric or parametric survival analysis methods, as appropriate. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
From date of Group 4 randomization to date of treatment failure, relapse, SMN or death due to any cause, assessed up to 5 years
|
|
Incidence of adverse events in Arm A or Arm B
기간: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events in Arm H or Arm I
기간: Up to 1 cycle of therapy (each cycle = 36 days)
|
The toxicities as defined by grade 3 or greater reported adverse events during the first cycle of blinatumomab or blinatumomab/nivolumab will be compared to similar patients treated with Block 1 of cytotoxic chemotherapy on AALL1331 using two-sample test of proportions. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Group 2)
기간: Up to 2 cycles of therapy (each cycle = 36 days)
|
MRD negative Rem-2 rate will be estimated and be compared between Arm C and Arm D using two-sample test of proportions. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Dose-limiting toxicity (Down syndrome patients)
기간: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
Incidence of adverse events (Down syndrome patients)
기간: Up to 1 cycle of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 1 cycle of therapy (each cycle = 36 days)
|
|
MRD negative Rem-2 rate (Down syndrome patients)
기간: Up to 2 cycles of therapy (each cycle = 36 days)
|
Analyses will be largely descriptive. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of EFS
기간: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. Cumulative incidence rates of each EFS event type will also be estimated and presented with cumulative incidence curves, and be compared between groups as appropriate. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
Subset analyses of OS
기간: Up to 2 cycles of therapy (each cycle = 36 days)
|
Features at first relapse including degree of marrow disease at relapse, age, sex, body mass index, cytogenetics, site(s) of relapse, percent peripheral blasts at relapse and absolute lymphocyte count, will be conducted. These analyses will be exploratory. |
Up to 2 cycles of therapy (each cycle = 36 days)
|
|
EFS PR (Group 4)
기간: At 2 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm H and I. |
At 2 years from date of randomization
|
|
EFS PR (Group 3)
기간: At 3 years from date of randomization
|
Corresponding 95% CIs by sex, by race, and by ethnicity separately for arm E and F. |
At 3 years from date of randomization
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Stacy L Cooper, Children's Oncology Group
간행물 및 유용한 링크
일반 간행물
- Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704.
- Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 신경학적 징후
- 신경계 질환
- 신생물
- 유전병, 선천적
- 면역계 질환
- 감염
- 바이러스 질환
- 조직학적 유형에 따른 신생물
- 신경 행동 징후
- DNA 바이러스 감염
- 림프계 질환
- 림프 증식 장애
- 면역증식성 장애
- 림프종, 비호지킨
- 선천적 이상
- 림프종, B세포
- 림프종
- 이상, 다중
- 지적 장애
- 엡스타인-바 바이러스 감염
- 헤르페스바이러스과 감염
- 종양 바이러스 감염
- 염색체 장애
- 선천성, 유전성, 신생아 질환 및 이상
- 헴 및 림프병
- 버킷 림프종
- 다운 증후군
- 호르몬
- 호르몬, 호르몬 대체제, 호르몬 길항제
- 아미노산, 펩티드 및 단백질
- 단백질
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 구멍
- 수술 절차, 수술
- 세포 학적 기술
- 핵산, 뉴클레오티드 및 뉴 클레오 시드
- 세포 진단
- 탄화수소
- 탄화수소, 순환
- 알칼로이드
- 탄화수소, 방향족
- 다 환식 화합물
- 가수 분해 효소
- 효소
- 효소 및 코엔자임
- 인돌
- 항체, 모노클로 날, 인간화
- 항체, 모노클로 날
- 항체
- 면역 글로불린
- 면역 단백질
- 혈액 단백질
- 혈청 글로불린
- 글로불린
- 퓨린
- 시티 딘
- 피리 미딘 뉴 클레오 시드
- 피리 미딘
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- 벤젠 유도체
- 진단 기술, 수술
- 설 폰산
- 황산
- 뉴 클레오 시드
- Pterins
- Teridines
- Pregnadienetriols
- 아미도 하이드로 라제
- Vinca 알칼로이드
- Secologanin Tryptamine 알칼로이드
- 인돌 알칼로이드
- 인돌리 지딘
- 인도인
- 아라비노 뉴 클레오 시드
- 아미노 테린
- 방사선 요법
- 임신 한
- 임신
- 11- 하이드 록시 코르티코 스테로이드
- 히드 록시 코르티코 스테로이드
- 부신 피질 호르몬
- 17- 하이드 록시 코르티코 스테로이드
- 진단 기술, 신경계
- 벤젠 설포 네이트
- 아릴 설포 네이트
- 아릴 설 폰산
- 방사선 요법, 컴퓨터 보조
- 설페이드릴 화합물
- 니볼루맙
- 덱사메타손
- 메토트렉세이트
- 시타라빈
- 빈크리스틴
- 하이드로코르티손
- 아스파라기나제
- 메르캅토퓨린
- 칼슘 도베실레이트
- 생검
- 시편 처리
- 블리나투모 맙
- 척추 천자
- 덱사메타손 21- 포스페이트
- N, N-Dicyclohexyl-Isoborneol-10-Sulfonamide
- Calaspargase Pegol
- 아자 티오 푸린
- 메르 포스
- 페가 스파 제
- 방사선 요법, 적합성
- 장막
- 덱사메타손 아세테이트
- 아스파라기나 제 Erwinia Chrysanthemi 재조합
- 하이드로 코르티손 헤 미소
기타 연구 ID 번호
기타 연구 ID 번호
- NCI-2020-06813
- U10CA180886 (미국 NIH 보조금/계약)
- NCI-2020-06813 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- AALL1821 (기타 식별자: CTEP)
- AALL1821 (기타 식별자: Children's Oncology Group)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .